tradingkey.logo

Zentek Ltd

ZTEK
0.654USD
+0.013+2.03%
Close 02/06, 16:00ETQuotes delayed by 15 min
68.60MMarket Cap
LossP/E TTM

Zentek Ltd

0.654
+0.013+2.03%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Zentek Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Zentek Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 220 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zentek Ltd's Score

Industry at a Glance

Industry Ranking
220 / 392
Overall Ranking
455 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Zentek Ltd Highlights

StrengthsRisks
Zentek Ltd. is an intellectual property technology company. The Company is focused primarily on commercializing ZenGUARD, as well as on the development of certain aptamer technologies and other nanomaterials-based technologies. ZenGUARD is the Company’s patented anti-microbial coating technology platform. Its platform, ZenGUARD, has been shown to have enhanced bacterial and viral filtration efficiency for surgical masks and heating, ventilation, and air conditioning (HVAC) systems. The Company is also focused on the research, development and commercialization of novel products, seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. The Company has installed industrial-scale production equipment to produce the ZenGUARD coating formulation. The Company is also working on developing processes to synthesize graphene, GO and graphene quantum dots, along with other possible applications for graphene-based materials.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 777.99% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 639.66K.
Fairly Valued
The company’s latest PE is -11.56, at a medium 3-year percentile range.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.65.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Zentek Ltd is 5.31, ranking 374 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 4.42K, representing a year-over-year decrease of 71.82%, while its net profit experienced a year-over-year decrease of 44.04%.

Score

Industry at a Glance

Previous score
5.31
Change
0

Financials

4.96

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.00

Operational Efficiency

2.83

Growth Potential

4.69

Shareholder Returns

7.07

Zentek Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Zentek Ltd is 7.31, ranking 139 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.56, which is -68.13% below the recent high of -3.68 and -61.96% above the recent low of -18.72.

Score

Industry at a Glance

Previous score
7.31
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 220/392
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Zentek Ltd. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Zentek Ltd is 6.58, ranking 219 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.96 and the support level at 0.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.54
Change
0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.042
Sell
RSI(14)
38.776
Neutral
STOCH(KDJ)(9,3,3)
11.422
Oversold
ATR(14)
0.078
Low Volatility
CCI(14)
-82.447
Neutral
Williams %R
88.628
Oversold
TRIX(12,20)
-0.525
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
0.648
Buy
MA10
0.697
Sell
MA20
0.788
Sell
MA50
0.747
Sell
MA100
0.783
Sell
MA200
0.974
Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Fenton (Gregory)
3.14M
+1.25%
Dube (Francis Jacques)
1.14M
+26.81%
Scotia Capital Inc.
881.20K
-1.95%
Van der Kuur (Colin Stuart)
571.33K
--
Wallman (Eric)
500.97K
+5.25%
RBC Dominion Securities, Inc.
271.43K
-4.21%
Wood (Peter)
237.72K
--
Shacklock (Ryan)
178.20K
--
Desjardins Securities Inc.
151.65K
+3.04%
CIBC World Markets Inc.
141.25K
--
1
2

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zentek Ltd is 2.84, ranking 193 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.84
Change
0
Beta vs S&P 500 index
0.42
VaR
+6.36%
240-Day Maximum Drawdown
+64.35%
240-Day Volatility
+111.92%

Return

Best Daily Return
60 days
+21.84%
120 days
+34.75%
5 years
+34.75%
Worst Daily Return
60 days
-9.43%
120 days
-9.43%
5 years
-17.45%
Sharpe Ratio
60 days
-0.71
120 days
-0.07
5 years
+0.10

Risk Assessment

Maximum Drawdown
240 days
+64.35%
3 years
+68.00%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.59
3 years
-0.28
5 years
--
Skewness
240 days
+2.22
3 years
+2.06
5 years
+1.56

Volatility

Realised Volatility
240 days
+111.92%
5 years
--
Standardised True Range
240 days
+13.37%
5 years
--
Downside Risk-Adjusted Return
120 days
-17.47%
240 days
-17.47%
Maximum Daily Upside Volatility
60 days
+71.53%
Maximum Daily Downside Volatility
60 days
+50.24%

Liquidity

Average Turnover Rate
60 days
+0.30%
120 days
+0.17%
5 years
--
Turnover Deviation
20 days
+1065.19%
60 days
+339.23%
120 days
+154.11%

Peer Comparison

Biotechnology & Medical Research
Zentek Ltd
Zentek Ltd
ZTEK
4.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI